RE:RE:RE:RE:RE:unfotunately, neither will this....Hi GV.
That was my perception as well. We are all different genetically and react to drugs differently so it's just natural that some patients bodies rejact negatively. However, the research findings indicated that even within many of those that had negative reactions when they came back to the statin on revised doseage or revised frequency they're were positive health effects...I guess the body had time to adjust.
From what I see one of the big movements in medicine is taylor made drugs i.e. this is clear recognition that we are all genetically different. So whereas flu vaccination covers the population with only 1% to 2% impacted negatively, many types of cancers and other diseases require specifically constructed drugs. This is now taking place.
Hence the enormous potential...to build epigenetic software to produce patient or sub-population specific to the patient and disease. This is ZENITH.
rvx-208 seems to have it's major positive impact on the high risk patients outlined in the February webcast. The key is how large is this market and Don said it was a $1.4 billion market in the USA alone...not even considering the resk of the world.
AND the great news is that any adverse effects were minor and brief and disappeared as time passed in the trial...seems too suggest that body adjusted to rvx-208.
I think your last point is key because increasing HDL seems to be emerging as a key platform for many diseases. So this provides options because it could be used with rosuvastatin for plaque regressiion in some patients and on it's own for sweeping up soft lipds that are unstable hence reducing MACE.
This is all IMO and based on my interpretation of what I'm beginning to see. Looks positive to me.
Cheers
Toinv